Efficacy and durability of Bacillus anthracis bacteriophages used against spores

Journal of Environmental Health

Volumn 66, Issue 1, 2003, Pages 9-15

  Walter, Michael H ^a  

^a UNIVERSITY OF NORTHERN IOWA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRAX; BACTERIOPHAGE; DISEASE CONTROL; SPORE;

AEROSOL; ANTHRAX; BACILLUS ANTHRACIS; BACTERIAL GROWTH; BACTERIAL SPORE; BACTERIOPHAGE; CONCENTRATION RESPONSE; DISINFECTION; FILTRATION; HEAT SENSITIVITY; NONHUMAN; REVIEW; RISK ASSESSMENT; SIMULATION;

ANTHRAX; BACILLUS ANTHRACIS; BACTERIOPHAGES; DECONTAMINATION; RISK ASSESSMENT; SPORES; TEMPERATURE; ULTRAVIOLET RAYS;

ANTHRAX; BACILLUS ANTHRACIS; BACTERIA (MICROORGANISMS); POSIBACTERIA; UNIDENTIFIED BACTERIOPHAGE;

EID: 0038001038     PISSN: 00220892     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (27)

1. Ackermann, H.W., Azizbekyan, R.R., Emadi Konjin, H.P., Lecadet, M.-M., Seldin, L., & Yu, M.X. (1994). New Bacillus bacteriophage species. Archives of Virology, 135(3-4), 333-344.
2. Ackermann, H.W., & Dubow, M.S. (1989). Viruses of prokaryotes: General properties of bacteriophages. Boca Raton, FL: CRC Press, Inc.
3. Adams, M.H. (1959). Bacteriophages. New York: Interscience Publishers, Inc.
4. Ahmad, S.I. (2002). Treatment of post-burns bacterial infections by bacteriophages, specifically ubiquitous Pseudomonas spp. notoriously resistant to antibiotics. Medical Hypotheses, 58(4), 327-331.
5. Akimkin, V.G., Bondarenko, V.M., Voroshilova, N.N., Darbeeva, O.S., & Baiguzina, F.A. (1998). [Practical use of adapted Salmonella bacteriophage for the treatment and prevention of nosocomial infections.] Zhurnal Mikrobiologii, Epidemiologii, i Immunobiologii, 6(November/December), 85-86.
6. Baker, S.L., & Nanvutty, S.H. (1929). A quantitative study of the effect of ultra-violet rays upon the bacteriophage. British Journal of Experimental Pathology, 10(1), 45-61.
7. Barrow, P., Lovell, M., & Berchieri, A.J. (1998). Use of lytic bacteriophage for control of experimental Escherichia coli septicemia and meningitis in chickens and calves. Clinical and Diagnostic Laboratory Immunology, 5(3), 294-298.
8. Biswas, B., Adhya, S., Washart, P., Paul, B., Trostel, A.N., Powell, B., Carlton, R., & Merril, C.R. (2002). Bacteriophage therapy rescues mice bacteremic from a clinical isolate of vancomycin-resistant Enterococcus faecium. Infection and Immunity, 70(1), 204-210.
9. Brookmeyer, R., & Blades, N. (2002). Prevention of inhalational anthrax in the U.S. outbreak. Science, 295(5561), 1861.
10. Brown, E.R., & Cherry, W.B. (1955). Specific identification of Bacillus anthracis by means of a variant bacteriophage. Journal of Infectious Diseases, 96(1), 34-39.
11. Cowles, P.B., & Hale, W.M. (1931). Effect of bacteriophage on experimental anthrax in white mice. Journal of Infectious Diseases, 49(3), 264-269.
12. Duckworth, D.H., & Gulig, P.A. (2002). Bacteriophages: Potential treatment for bacterial infections. BioDrugs, 16(1), 57-62.
13. Harrell, L.J., Andersen, G.L., & Wilson, K.H. (1995). Genetic variability of Bacillus anthracis and related species. Journal of Clinical Microbiology, 33(7), 1847-1850.
14. Helgason, E., Okstad, O.A., Caugant, D.A., Johansen, H.A., Fouet, A., Mock, M., Hegna, I., & Kolsto, A.-B. (2000). Bacillus anthracis, Bacillus cereus, and Bacillus thuringiensis - One species on the basis of genetic evidence. Applied and Environmental Microbiology, 66(6), 2627-2630.
15. Jernigan, J.A., Stephens, D.S., Ashford, D.A., Omenaca, C., Topiel, M.S., Galbraith, M., Tapper, M., Fisk, T.L., Zaki, S., Popovic, T., Meyer, R.F., Quinn, C.P., Harper, S.A., Fridkin, S.K., Sejvar, J.J., Shepard, C.W., McConnell, M., Guarner, J., Shieh, W.J., Malecki, J.M., Gerberding, J.L., Hughes, J.M., & Perkins, B.A. (2001). Bioterrorism-related inhalational anthrax: The first 10 cases reported in the United States. Emerging Infectious Diseases, 7(6), 933-944.
16. Koper, O.B., Klabunde, J.S., Marchin, G.L., Klabunde, K.J., Stoimenov, P., & Bohra, L. (2002). Nanoscale powders and formulations with biocidal activity toward spores and vegetative cells of Bacillus species, viruses, and toxins. Current Microbiology, 44(1), 49-55.
17. Kudva, I.T., Jelacic, S., Tarr, PI., Youderian, P., & Hovde, C.J. (1999). Biocontrol of Escherichia coli O157 with O157-specific bacteriophages. Applied and Environmental Microbiology, 65, 3767-3773.
18. Luria, S.E., & Delbrück, M. (1942). Interference between bacterial viruses: II. Interference between inactivated bacterial virus and active virus of the same strain and of a different strain. Archives of Biochemistry, 1(2), 207-218.
19. McCloy, E.W. (1951). Studies on a lysogenic Bacillus strain. I. A bacteriophage specific for Bacillus anthracis. Journal of Hygiene, 49(1), 114-125.
20. Merril, C.R., Biswas, B., Carlton, R., Jensen, N.C., Creed, G.J., Zullo, S., & Adhya, S. (1996). Long-circulating bacteriophage as antibacterial agents. Proceedings of the National Academy of Sciences United States of America, 93, 3188-3192.
21. Moreno, E (1979). On the trapping of phage genomes in spores of Bacillus subtilis 168. Reciprocal exclusion of phages phi29 and phie during outgrowth of spores. Virology, 93(2), 357-368.
22. Nelson, D., Loomis, L., & Fischetti, V.A. (2001). Prevention and elimination of upper respiratory colonization of mice by group A streptococci by using a bacteriophage lytic enzyme. Proceedings of the National Academy of Sciences of the United States of America, 98, 4107-4112.
23. Payne, R.J., & Jansen, V.A. (2001). Understanding bacteriophage herapy as a density-dependent kinetic process. Journal of Theoretical Biology, 208(1), 37-48.
24. Schuch, R., Nelson, D., & Fischetti, V.A. (2002). A bacteriolytic agent that detects and kills Bacillus anthracis. Nature, 418, 884-889.
25. Summers, W.C. (2001). Bacteriophage therapy. Annual Reviews of Microbiology, 55, 437-451.
26. Thorne, C.B. (1968). Transducing bacteriophage for Bacillus cereus. Journal of Virology, 2(7), 657-662.
27. Weber-Dabrowska, B., Zimecki, M., & Mulczyk, M. (2000). Effective phage therapy is associated with normalization of cytokine production by blood cell cultures. Archivum Immunologiae et Therapiae Experimentalis, 48(1), 31-37.